Dr. David J. Earp steps down as Sienna board member


Melbourne, Australia, 14 November 2019: Sienna Cancer Diagnostics Ltd (ASX: SDX) (“Sienna” or “the Company”), wishes to advise that long standing and highly respected Non-executive Director, David J. Earp, JD, PhD has stepped down effective at the end of today’s Annual General Meeting (AGM).

“It has been my privilege to serve on the Sienna board for the last 7 years. I have greatly appreciated working closely with my colleagues on the board and the whole team at Sienna,” said Dr. Earp. “Over my time on the board, Sienna has progressed from an early stage discovery company through to its first launched product, commercial sales and an ASX listing. And today Sienna stands with a new platform technology from its recent acquisition of Sevident’s technology. That technology promises to open up significant new and large market opportunities for Sienna, including in liquid biopsy and especially in the emerging exosome space. I look forward to seeing the company’s continued progress in the months and years ahead.”

Sienna’s Chairman, Geoff Cumming said, “We are deeply grateful for David’s seven years of service to Sienna; his departure is a loss for the board and the company. He has been a diligent director who has contributed critical analysis on a broad range of issues, offered valuable guidance on matters of governance and delivered great insights in his particular areas of expertise, IP and partnering strategy”.


No Very

Captcha Image

Sign up for updates